Prkdc and Il2rg genes were both knocked-out in NOD mice.
- Lacking mature T, B and NK cells
- Low immune rejection against human cells and tissues
- Good tumorigenicity so that a small number of cells can form tumors.
- Significant improvement in the survival of transplanted human cells and tissues
- Suitable for the transplantation of human hematopoietic stem cells and the preparation of humanized mouse models
- Suitable as the carrier mice for the transplantation of heterologous cells and tissues
Figure 1. Complete deletion of T, B and NK cells in the spleen of M-NSG mice.(A) The splenocytes of BALB/c, NOD-scid and M-NSG mice were collected to analyze their compositions of T, B and NK cells by FACS. (B) Statistical analysis of sorted cells.
Figure 2. Complete deletion of T, B and NK cells in the blood of M-NSG mice.(A) The peripheral blood samples of BALB/c, NOD-scid and M-NSG mice were collected to analyze their compositions of T, B and NK cells by FACS.(B) Statistical analysis of sorted cells.
Figure 3. Compositions of monocytes, macrophages, DCs in the spleen of M-NSG mice. (A) The splenocytes of BALB/c, NOD-scid and M-NSG mice were collected to analyze their compositions of monocytes, macrophages, DCs. (B) Statistical analysis of sorted cells.
Figure 4. Compositions of monocytes, macrophages, DCs in the blood of M-NSG mice. (A) The peripheral blood samples of BALB/c, NOD-scid and M-NSG mice were collected to analyze their compositions of monocytes, macrophages, DCs. (B) Statistical analysis of sorted cells.
Fiugure 5. Spleen from M-NSG mouse shows complete loss of white pulps(10×).
Compared with C57BL/6 mice, the spleen of NSG mice lacked white pulp containing a large number of lymphocytes and the thymus are atrophied.
Figure 6. Histological sections of various tissues from M-NSG mice. Furthermore, no significant abnormalities were observed in other tissues, including brain, retina, spinal cord, heart, liver, lung, kidney, small intestine, large intestine, stomach, salivary glands, pancreas, ovary, uterus, testis, epididymis, skeletal muscle, skin, and brown fat.
Fig7. Serum antibody response in the serum of BALB/c, NOD-SCID, M-NSG and Blank.
Fig9. The establishment of tumor models using A549 or Raji cells is more effective in M-NSG mice.
A CDX model has been successfully established in M-NSG mice
Fig10. In vivo Efficacy Study of Anti-human CD47 Reference Antibody in the Treatment of Raji lymphoma CDX Tumor model in M-NSG mice.
Fig11. CAR-T in vivo efficacy study of A549 NSCLC model in M-NSG mice
Fig12. PBMC reconstitution model. Human PBMC cells were intravenous implanted into homozygote M-NSG mice. Percentage of human CD45+ cells (A), body weight (B).
Fig13. In vivo Efficacy Study of Hu-PBMC Reconstruction Model in M-NSG mice.
Fig14. Analysis of peripheral blood lymphocyte subpopulations of M-NSG mice after implantation of human CD34+ HSC at different times.
Fig15. Drug efficacy evaluation study performed in M-NSG mice reconstituted with hCD34+ cells. Humanized M-NSG mice reconstituted with human CD34+ cells were i.v. injected with MDA-MB-231 cells.
Peptide Self-Assembly Nanoparticles Loaded with Panobinostat to Activate Latent Human Immunodeficiency Virus
References：J Biomed Nanotechnol
SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation
A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity
References：SCI TRANSL MED
Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
References：Frontiers in Immunology
T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
A Chimeric Conjugate of Antibody and Programmable DNA Nanoassembly Smartly Activates T cell for Precise Cancer Cell Targeting
References：A Journal of the Gesellschaft Deutscher Chemiker
Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer
당신은 또한 좋아할 수 있습니다
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.조회
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.조회